Results 31 to 40 of about 1,482,290 (356)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

open access: yesPLoS ONE, 2016
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of ...
Michael K Kiessling   +8 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

open access: yesTechnology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM   +2 more
doaj   +1 more source

Risk factors for thromboembolism during first-line treatment of patients with unresectable advanced or recurrent colorectal cancer: a retrospective short study

open access: yesJournal of Pharmaceutical Health Care and Sciences, 2023
Background While cancer is a risk factor for developing thromboembolism, so is the use of molecularly targeted therapies. This study aimed to determine whether thromboembolism incidence differed between vascular endothelial growth factor (VEGF) and ...
Ryo Takada   +4 more
doaj   +1 more source

The Azadirachtins: potent insect growth inhibitors

open access: yesMemorias do Instituto Oswaldo Cruz, 1987
In the course of their coevolution with insects, plants have learnt to protect themselves by chemical means. Semiochemical act as antifeedants or deterrents, others by disrupting growth and development.
Heinz Rembold
doaj   +1 more source

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. [PDF]

open access: yes, 2016
Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure remains elusive. While immune-checkpoint antibodies are promising, interferon-based immunotherapy has been disappointing.
Abu Aboud, Omran   +13 more
core   +2 more sources

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

open access: yesThoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi   +10 more
doaj   +1 more source

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

open access: yes, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T   +14 more
core   +1 more source

The Serine/Threonine Protein Kinase (Akt)/ Protein Kinase B (PkB) Signaling Pathway in Breast Cancer [PDF]

open access: yes, 2020
According to statistical data published in 2019, breast cancer is among the leading causes of death in women worldwide. The serine/threonine kinase (AKT) or protein kinase B (PkB) signaling pathway is activated by phosphorylation processes, which further
Bratu, Ovidiu Gabriel   +8 more
core   +3 more sources

The Utilization of Plant Growth Regulators (PGRs) in Agricultural Application and The Effecting Mechanisms

open access: yesResearch in Agricultural Sciences
Plants, which lack a sophisticated endocrine system, utilize growth regulators (phytohormones) naturally produced within their bodies to grow, develop, and respond to environmental factors.
Büşra Yirmibeş   +3 more
doaj   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

open access: yesTumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Home - About - Disclaimer - Privacy